Calliditas Therapeutics AB

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

STOCKHOLM , Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm.

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg.

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions.

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Therapeutics AB (publ) (NASDAQ:CALT ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Renée Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson - CFO Conference Call Participants Operator Welcome to Calliditas Q2 2024 Report. [Operator Instructions] And there will be no Q&A session after the presentation.

Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript

STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.

Calliditas Interim Report January to June 2024

STOCKHOLM , July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the company's long-term incentive program issued in 2020, ESOP 2020 and Board of Directors program LTIP 2021. As of today, the total number of outstanding shares in Calliditas Therapeutics AB (publ) amounts to 59,941,465 ordinary shares.

Number of shares and votes in Calliditas Therapeutics

Atrion

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atrion Corporation (NASDAQ: ATRI)'s sale to Nordson Corporation for $460.00 per share in cash. If you are an Atrion shareholder, click here to learn more about your legal rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT ), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding shares of Calliditas stock for SEK 0.04 in cash per ADS.

STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT

NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT

STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission has granted a full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN).

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo. The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness.

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).

Launch of Phase 3 clinical trial with Nefecon in Japan

STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer.

Calliditas provides setanaxib patent update

STOCKHOLM , June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023.

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Akili Inc

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating: Akili, Inc. (NASDAQ: AKLI ), relating to a tender offer from Vital Therapeutics Corporation.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB ( NASDA Q: CALT ), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding shares of Calliditas stock for SEK 0.04 in cash per ADS.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB – CALT

Model N

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Model N, Inc. (NYSE:MODN)'s sale to Vista Equity Partners for $30.00 per share. If you are a Model N shareholder, click here to learn more about your rights and options.

SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate MODN, CALT

NEW YORK , June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALT

STOCKHOLM , May 30, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of full marketing authorisation for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). Kinpeygo, which was granted conditional marketing authorisation in EU on 15 July 2022, was the first ever approved treatment for IgAN in the EU and UK.

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

Calliditas Therapeutics AB's American depositary receipts CALT, -1.45% jumped more than 70% premarket on Tuesday after a nearly $1.1 billion takeover bid from Japanese conglomerate Asahi Kasei.

Calliditas Therapeutics' stock surges after $1.1 billion takeover bid

STOCKHOLM , May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN). These were presented at ERA 2024 virtually and in Stockholm on May 23 - 26, 2024.

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Calliditas Therapeutics AB (NASDAQ: CALT) to Asahi Kasei Corporation for SEK 416 in cash per American Depositary Share is fair to Calliditas shareholders. Halper Sadeh encourages Calliditas shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The inv.

CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders

Asahi Kasei Corp

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Corp. (TOKYO:3407) today announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei (“the Acquisition”) through a voluntary tender offer for Calliditas (“the Tender Offer”). The Tender Offer will also include a concurrent offer by Asahi Kasei to acquire all American Depos.

News for Calliditas Therapeutics AB Stock (CALT)